XRCC1基因多态性与晚期非小细胞肺癌铂类化疗敏感性的研究  

Polymorphism in XRCC1 and Sensitivity to Platin-based Chemotherapy in Advanced Non-small Cell Lung Cancer

作　　者：丁春雷[1,2] 刘丽宏[2] 宋海峰[1] 

机构地区：[1]军事医学科学院,北京100850 [2]第二炮兵总医院

出　　处：《中国药师》2010年第10期1399-1401,共3页China Pharmacist

摘　　要：目的:研究XRCC1基因多态性与非小细胞肺癌(NSCLC)患者对铂类为基础的联合化疗的敏感性。方法:收集我院NSCLC患者54例,提取外周白细胞DNA,采用多重PCR对XRCC1 194,399两个多态性位点同时扩增,对扩增产物进行纯化后直接测序,判定基因分型。结果:携带XRCC1 399 Arg/Arg的化疗有效率是Gln/Gln的2.5倍(P=0.035,95%CI=0.892～7.094)。携带一个Gln等位基因的化疗失败风险是携带Arg/Arg的1.7倍(P=0.044,95%CI=1.012～2.720)。未发现XRCC1 194不同基因型对铂类化疗敏感性有差异。结论:XRCC1 399Gln/Arg基因多态性与晚期NSCLC接受铂类为基础的化疗敏感性相关。Objective： To study the relationship of XRCC1 gene polymorphisms with chemosensitivity to platinum-based chemotherapy in advanced non-small cell lung cancer. Method ： Fifty-four cases of NSCLC were analyzed, DNA of peripheral blood leukoeytes was extractd, XRCC1 194,399 genotypes were detected by multi-PCR and sequencing. Result： The response rate to platin-based chemotherapy with XRCC 1 399 Arg/Arg was 2. 5 times higher than that with Gln/Gln （P = 0. 035,95 % CI = 0. 892-7. 094 ）. The failure rate with Gin allele was 1.7 times higher than that with Arg/Arg（P =0. 044,95% CI = 1. 012-2. 720）. There was no difference of the response rate to platin-based chemotherapy with the XRCC1 194 polymorphfsm. Conclusion： Polymorphisms in the XRCC1 399 Gln/Arg may have significant impact on the response of NSCLC patients to platin-based chemotherapy.

关 键 词：多重PCR XRCC1 铂类 化疗敏感性 非小细胞肺癌 

分 类 号：R968[医药卫生—药理学]